NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens by Schultz-Thater, E et al.
Tumour-associated antigens (TAA) of the cancer testis (CT)
family are characterized by a peculiar expression pattern since the
corresponding genes are transcribed in healthy testis and in a
number of histologically unrelated tumours (Boon and van der
Bruggen, 1996; Chen et al, 1998). In particular, epitopes from
different MAGE TAA have been shown to be recognized by
specific cytotoxic T cells (CTL), and, more recently, to induce
class II restricted T cell responses (Boon and van der Bruggen,
1996; Chaux et al, 1999; Manici et al, 1999). Clinical trials based
on the use of these antigens have been initiated and promising
preliminary results have been reported (Marchand et al, 1995;
Marchand et al, 1999; Nestle et al, 1999; Thurner et al, 1999).
Recently, novel members of the CT TAA family have been
identified by taking advantage of a newly devised technique,
SEREX (Sahin et al, 1995; Türeci et al, 1998), that relies on the
recognition of target molecules by specific antibodies present in
patients’ sera. One of them, NY-ESO-1, emerges as a potential
candidate for the inclusion in therapeutic vaccine preparations
since it encompasses both humoral and CTL target epitopes (Chen
et al, 1997; Jäger et al, 1998; Wang et al 1998).
We and others have previously generated monoclonal anti-
bodies (mAbs) specific for MAGE family CT TAA (Chen et al,
1994; Schultz-Thater et al, 1994; Kocher et al, 1995; Carrel et al,
1996; Jurk et al, 1998). By demonstrating the widespread expres-
sion of target determinants in defined tumour types, these reagents
support the implementation of specific immunization procedures
(Gudat et al, 1996; Hofbauer et al, 1997). So far, NY-ESO-1
specific mAb identifying this TAA in ‘western blot’ assays have
been reported (Jäger et al, 1998), but no reagents capable of recog-
nizing it in cytological or histological preparations have been
described.
We report here on the generation and characterization of mAbs
recognizing NY-ESO-1 TAA, permitting its identification as a
cytoplasmic protein detectable in discrete cell lines and clinical
tumour samples.
MATERIALS AND METHODS
Cell lines
D10, MZ-2 and A375 cell lines are gifts of Dr Rimoldi (Ludwig
Institute, Lausanne, Switzerland). HBL and S7 cell lines were
kindly provided by Drs Ghanem (Free University of Brussels,
Belgium) and Shibahara (Tohoku University, Sendai, Japan),
respectively. RE cell line is a gift of Dr Siegrist (University of
Basel, Switzerland), whereas WM-266 cell line was obtained from
American Type Culture Collection (Rockville, MD). SK-MEL-37
cell line is a gift of Dr Jungbluth (Ludwig Institute at Memorial
Sloan Kettering Cancer Center, New York, NY).
Preparation of NY-ESO-1 fusion protein
NY-ESO-1 entire gene (courtesy of Dr Sahin, Homburg/Saar,
Germany) was cloned into pET-32a vector (Novagen, Madison,
WI) allowing inducible expression of inserted genes in the form
of fusion proteins containing thioredoxin and a six histidin tail.
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After a three hour induction in the presence of IPTG (1 mM final
concentration) bacterial cultures were spun down and recombi-
nant proteins were purified under native conditions upon binding
to nickel resins (Ni-NTA, Qiagen, Basel, Switzerland) and elution
in the presence of 250 mM imidazole. Production and purification
of the recombinant proteins were monitored by SDS-PAGE and
Coomassie blue staining (Schultz-Thater et al, 1994).
Production of monoclonal antibodies
BALB/c mice were repeatedly injected i.p. at two week intervals
with 100 mg Ni purified material containing NY-ESO-1 gene
product. The first immunization included complete Freund’s adju-
vant, whereas the second and third were performed in the presence
of incomplete Freund’s adjuvant. Three days after a last injection
in the absence of adjuvant preparations, animals were sacrificed
and fusions were carried out as previously detailed (Schultz-Thater
et al, 1994). Screening of HAT resistant hybridoma supernatants
was performed by ELISA.
Detection of NY-ESO-1 gene expression
Total cellular RNA was extracted from the cell lines under investi-
gation (see above), reverse transcribed and tested in 25 cycles RT-
PCR assays in the presence of primer pairs specific for b-actin
positive control gene yielding a 661 bp amplicon (Schultz-Thater
et al, 1994) or NY-ESO-1 gene yielding a 354 bp amplicon (Chen
et al, 1997). Each cycle included a 30 s denaturation step at 94°C,
a 40 s annealing step at 72°C and a 40 s extension at 72°C. RT-
PCR products were run on 1.5% agarose gels in the presence of
ethidium bromide and photographs were taken under UV transillu-
mination.
Immunocytochemistry and immunohistochemistry
Acetone fixed cytospin preparations of the indicated melanoma
cell lines were incubated in the presence of undiluted control or
specific hybridoma supernatants for 30 min at room temperature.
Frozen tumour sections were thawed, washed in PBS, fixed in
paraformaldehyde-lysine-periodate (Gudat et al, 1996) or buffered
formalin and incubated overnight at 4°C in the presence of
hybridoma supernatants. For both preparations, bound antibodies
were visualized by using the APAAP method according to the
recommendations of the supplier (DAKOPATTS A/S, Glostrup,
Denmark).
RESULTS
Production of recombinant NY-ESO-1
NY-ESO-1 entire open reading frame was subcloned into the pET
32a inducible expression vector. Upon IPTG treatment, the TAA
could be successfully produced in soluble form in the context of a
fusion protein, inclusive of thioredoxin and a poly-histidin tail
(data not shown). Following purification on nickel columns, the
fusion protein comprising NY-ESO-1 TAA was detectable in
Coomassie blue stained gels with an apparent molecular weight of
46 kDa. This material was used to immunize mice and screen
hybridomas. Similarly produced soluble thioredoxin served as
negative control in screening procedures.
Generation of NY-ESO-1 specific mAbs recognizing
recombinant and native gene products
Five mAbs (B4.2, IgG2a; B9.8, IgG1; B10.3, IgG1, D8.10, IgG1
and D8.38, IgG1) appeared to recognize specifically recombinant
NY-ESO-1 protein in ELISA assays. In order to assess the capacity
of the mAbs produced to identify the native protein, eight
melanoma cell lines were characterized in terms of expression of
NY-ESO-1 gene by 25 cycles RT-PCR. All lines expressed b-actin
house-keeping gene, whereas NY-ESO-1 gene expression was
only detectable in positive control SK-Mel 37 (Jäger et al, 1998)
and in RE cell lines (Figure 1, panels A and B). Lysates from all
cell lines were then tested together with the recombinant fusion
protein in immunoblot assays in the presence of the mAbs under
investigation. All reagents recognized the positive control recom-
binant fusion protein (Figure 1, panel C, lane R). Most impor-
tantly, they identified a single band of an apparent molecular
weight of 24 kDa, in lysates from both SK-MEL-37 and RE cell
lines, expressing NY-ESO-1 gene, as detectable in RT-PCR assays.
Representative data obtained by using B9.8 mAb are shown in
Figure 1, panel C. In contrast, no reactivity could be observed
against lysates derived from D10, HBL, MZ-2, S7, A375 or
WM266 melanoma cell lines. Indeed, these lines failed to express
NY-ESO-1 gene, although some of them expressed MAGE family
TAA (Kocher et al, 1995).
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Figure 1 Immunochemical detection of NY-ESO-1 gene product in
melanoma cell lines. Total cellular RNA was extracted from D10, HBL, MZ-2,
S7, SK-MEL-37, A375, RE and WM-266 cell lines (lanes 1 to 8, respectively),
reverse transcribed and amplified in 25 cycles RT-PCR in the presence of b-
actin specific (panel A) or NY-ESO-1 (panel B) specific primers. Amplification
products were run in the presence of ethidium bromide on agarose gels that
were then photographed under UV transillumination. Lysates from the same
cell lines (lanes 1 to 8, respectively) and the recombinant fusion protein
containing NY-ESO-1 gene product (lane R) were run on PAGE under
reducing conditions. Gels were then blotted and assayed in the presence of
B9.8 hybridoma supernatantImmunocytochemical recognition of NY-ESO-1 TAA by
specific mAbs
The identification of the target TAA in tumour cell lines was then
attempted. Cytospin preparations of D10 or SK-MEL-37 cells
were incubated in the presence of hybridoma supernatants,
including appropriate isotype matched reagents and specific
binding was revealed by APAAP method. Neither cell line was
stained by irrelevant control mAb (data not shown). On the other
hand, upon incubation with the mAbs under investigation, D10
cells scoring negative in PCR assays for NY-ESO-1 gene expres-
sion were not stained, whereas a strong cytoplasmic reactivity was
indeed detectable in PCR positive SK-MEL-37 cells. Interestingly,
in the latter cells no evidence of surface expression of the 
target antigen could be observed in flow-cytometry studies.
Representative examples, obtained following staining of the 
two cell lines with B9.8 mAb are reported in Figure 2 
(panels A and B).
Detection of NY-ESO-1 gene product in clinical tumour
samples
The possibility to detect NY-ESO-1 protein was then investigated
in a series of 12 melanomas. Expression of NY-ESO-1 gene
was first tested by 30 cycles RT-PCR. While positive control 
b-actin gene was found to be expressed in all samples, NY-ESO-1
transcripts were only amplified, to different extents, in five
specimens (Figure 3, panel B). Fresh frozen sections were then
studied in immunohistochemistry. Indeed, staining of tumour cells
was observed in the specimens where evidence of specific gene
transcription had been reported (Table 1). Percentages of cells
showing expression of different intensity ranged between single
cells and over 90% of neoplastic cells. Importantly, the staining,
mostly detectable in the cell cytoplasm, appeared to be limited to
cancer cells. Figure 2, panels C and D depicts sections from case
no 9, as described in Table 1.
DISCUSSION
NY-ESO-1 gene encodes a novel member of the CT TAA family
(Chen et al, 1997; Jäger et al, 1998; Wang et al, 1998).
Interestingly, NY-ESO-1 TAA has been shown to represent the
molecular target of humoral immune responses in relatively high
percentages of tumour patients (Stockert et al, 1998). Most impor-
tantly, HLA-A2 restricted epitopes recognized by CTL have been
demonstrated (Jäger et al, 1998; Wang et al, 1998). NY-ESO-1
gene product was identified in immunoblots as a 22-kDa protein
by a specific mAb (Jäger et al, 1998) but no data were reported
concerning immunocytochemical and immunohistochemical
detection or intracellular location.
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Figure 2 Immunocytochemical and immunohistochemical detection of NY-ESO-1 gene product. Acetone fixed cytospin preparations of D10 or SK-MEL-37
(panels A and B) cells were incubated in the presence of B9.8 mAb. Fresh frozen sections from a nodular primary melanoma showing evidence of NY-ESO-1
gene expression (case no 9 from Table 1), were tested in the presence of control mAb (panel C) or B9.8 mAb (panel D). For all preparations specific mAb
binding was revealed by APAAP technique. Melanin containing tumour cells are visible in panel C
D B
C AWe have produced NY-ESO-1 specific mAbs by using as
immunogen a recombinant fusion protein including the TAA under
investigation together with thioredoxin. These reagents recognize
the native protein in lysates of melanoma cell lines expressing the
specific gene in the apparent absence of cross-reactivities with
other CT TAA such as MAGE family determinants. Most impor-
tantly, the NY-ESO-1 target molecule can be identified by these
mAbs in immunocytological and immunohistological prepara-
tions. The specificity of this recognition is strongly supported by
RT-PCR and immunoblot data, as related to the cell lines and
tissues tested. Clearly, however, the possibility of cross reactivities
within a family of highly homologous determinants (Lethé et al,
1998), similarly to MAGE TAA, cannot be formally ruled out (Van
Baren et al, 1999).
Although sharing defined characteristics, NY-ESO-1 and
MAGE TAA display specific features. At difference with MAGE,
NY-ESO-1 gene is expressed in ovary tissue (Chen et al, 1997).
Furthermore, NY-ESO-1 molecule appears to contain a C-terminal
hydrophobic tail, potentially serving as membrane-associated
domain (Chen et al, 1997), whereas MAGE family TAA do not.
MAGE gene products are mostly characterized by a cytoplasmic
location (Chen et al, 1994; Schultz-Thater et al, 1994; Kocher 
et al, 1995; Carrel et al, 1996). However, MAGE-11 protein has
been shown to be prevailingly detectable in nuclei (Jurk et al,
1998).
Our data indicate that NY-ESO-1 gene product is detectable as 
a cytoplasmic protein in both cultured cell lines and clinical
melanoma specimens, whereas no obvious evidence of specific
staining of cell surfaces or nuclei was observed. Clearly, ultrastruc-
tural studies are required to clarify the role, if any, played by NY-
ESO-1 potential transmembrane domain in intracellular location.
Staining with specific mAbs reveals intratumour heterogeneity
in the expression of NY-ESO-1 TAA. Moreover, tumour cells
displaying different staining intensities can be detected, closely
resembling the MAGE TAA expression pattern (Gudat et al, 1996;
Hofbauer et al, 1997). It is remarkable, however, that in a subgroup
of the melanoma specimens tested in this work NY-ESO-1 gene
product appears to be detectable in >90% of neoplastic cells.
Although larger studies are obviously required, it is tempting to
speculate that, in these patients, NY-ESO-1 derived epitopes could
represent critical components of vaccine preparations.
The reagents described here together with the previously
reported MAGE family specific mAbs could allow the evaluation
of whether CT TAA expression is clustered in discrete cellular
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Table 1 Detection of NY-ESO-1 gene product in melanoma
Case no Diagnosis Localization RT-PCRa Positive cellsb Intensityc
1 Metastatic Lymphnode + <50% +/++
2 Metastatic Lymphnode +/– single cells +/++
3 Metastatic Lymphnode – – –
4 Metastatic Lymphnode – – –
5 Metastatic Skin – – –
6 Metastatic Lymphnode – – –
7 Metastatic Lymphnode – – –
8 Metastatic Lymphnode + >90% +/++
9 Primary – + >90% +/+++
10 Metastatic Lymphnode – – –
11 Metastatic Skin – – –
12 Metastatic Skin + <50% +/++
a RT-PCR data are reported in Figure 3, panel B; b Number of cells showing positive staining upon incubation with B9.8
mAb; c Intensity of reaction: + = weak, ++ = medium, +++ = strong
1            2            3            4            5            6              7           8            9            10          11           12
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Figure 3 Total cellular RNA was extracted from 12 different melanoma specimens (see Table 1), reverse transcribed and amplified in 30 cycles RT-PCR in the
presence of b-actin specific (panel A) or NY-ESO-1 (panel B) specific primers. Amplification products were run in the presence of ethidium bromide on agarose
gels that were then photographed under UV transillumination208 E Schultz-Thater et al
British Journal of Cancer (2000) 83(2), 204–208 © 2000 Cancer Research Campaign
subsets or can be detected independently for discrete gene fami-
lies. Furthermore, considering their relatively high specificity for
neoplastic cells, they could be of use in complementing defined
diagnostic and staging procedures.
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